

Citations

1. Blumenthal M, Busse W, Goldberg A et al. The Complete German Commission E Monographs. Austin, Texas: American Botanical Council: Integrative Medicine Communications; 1998.
2. WHO. *Rhizoma curcumae longae*. WHO Monographs on Selected Medicinal Plants. 1 vol. Geneva: World Health Organization; 1999:115-124.
3. ESCOP. *Curcumae longae rhizoma*. ESCOP Monographs: the Scientific Foundation for Herbal Medicinal Products. 2nd ed. Exeter, UK: European Scientific Cooperative on Phytotherapy and Thieme; 2003:107-117.
4. Aggarwal B, Kumar A, Aggarwal M, Shishodia S. Curcumin derived from turmeric (*Curcuma longa*): a spice for all seasons. In: Bagchi D, Preuss H, eds. *Phytopharmaceuticals in Cancer Chemoprevention*. Boca Raton, Fla: CRC Press; 2005:349-387.
5. Frawley D, Lad V. *The Yoga of Herbs*. Twin Lakes, Wis: Lotus Press; 1986.
6. Bensky D, Clavey S, Stögér E, Gamble A, Yu Jin. *Chinese Herbal Medicine: Materia Medica*. 3rd ed. Seattle: Eastland Press; 2004:609-612.
7. Mills S, Bone K. *The Essential Guide to Herbal Safety*. St Louis: Churchill Livingstone; 2005.
8. Chen J, Chen T. *Chinese Medical Herbology and Pharmacology*. City of Industry, Calif: Art of Medicine Press Inc; 2004.
9. Chainani-Wu N. Safety and anti-inflammatory activity of curcumin: a component of tumeric (*Curcuma longa*). *J Altern Complement Med* 2003;9:161-168.
10. Kang G, Kong PJ, Yuh YJ et al. Curcumin suppresses lipopolysaccharide-induced cyclooxygenase-2 expression by inhibiting activator protein 1 and nuclear factor kappa B bindings in BV2 microglial cells. *J Pharmacol Sci* 2004;94:325-328.
11. Yeh C-H, Chen T-P, Wu Y-C et al. Inhibition of NF- κ B activation with curcumin attenuates plasma inflammatory cytokines surge and cardiomyocytic apoptosis following cardiac ischemia/reperfusion. *J Surg Res* 2005;125:109-116.
12. Prusty BK, Das BC. Constitutive activation of transcription factor AP-1 in cervical cancer and suppression of human papillomavirus (HPV) transcription and AP-1 activity in HeLa cells by curcumin. *Int J Cancer* 2005;113:951-960.
13. Aggarwal BB, Takada Y, Oommen OV. From chemoprevention to chemotherapy: common targets and common goals. *Expert Opin Invest Drugs* 2004;13:1327-1338.
14. Yoysungnoen P, Wirachwong P, Bhattarakosol P et al. Effects of curcumin on tumor angiogenesis and biomarkers, COX-2 and VEGF, in hepatocellular carcinoma cell-implanted nude mice. *Clin Hemorheol Microcirc* 2006;34:109-115.
15. Hemaiswarya S, Doble M. Potential synergism of natural products in the treatment of cancer. *Phytother Res* 2006;20:239-249.
16. Verma SP, Goldin BR. Copper modulates activities of genistein, nitric oxide, and curcumin in breast tumor cells. *Biochem Biophys Res Commun* 2003;310:104-108.
17. Santibanez JF, Quintanilla M, Martinez J. Genistein and curcumin block TGF- β 1-induced u-PA expression and migratory and invasive phenotype in mouse epidermal keratinocytes. *Nutr Cancer* 2000;37:49-54.
18. Verma SP, Salamone E, Goldin B. Curcumin and genistein, plant natural products, show synergistic inhibitory effects on the growth of human breast cancer MCF-7 cells induced by estrogenic pesticides. *Biochem Biophys Res Commun* 1997;233:692-696.
19. Somasundaram S, Edmund NA, Moore DT et al. Dietary curcumin inhibits chemotherapy-induced apoptosis in models of human breast cancer. *Cancer Res* 2002;62:3868-3875.
20. Mitchell TM. Correspondence re: Somasundaram et al., Dietary curcumin inhibits chemotherapy-induced apoptosis in models of human breast cancer. *Cancer Res* 62:3868-3875, 2002. *Cancer Res* 2003;63:5165-5166; author reply 5166-5167.
21. Khafif A, Hurst R, Kyker K et al. Curcumin: a new radio-sensitizer of squamous cell carcinoma cells. *Otolaryngol Head Neck Surg* 2005;132:317-321.
22. Khopde SM, Priyadarsini KI, Guha SN et al. Inhibition of radiation-induced lipid peroxidation by tetrahydrocurcumin: possible mechanisms by pulse radiolysis. *Biosci Biotechnol Biochem* 2000;64:503-509.
23. Van't Land B, Blijlevens NM, Marteiijn J et al. Role of curcumin and the inhibition of NF- κ B in the onset of chemotherapy-induced mucosal barrier injury. *Leukemia* 2004;18:276-284.
24. Cheng AL, Hsu CH, Lin JK et al. Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. *Anticancer Res* 2001;21:2895-2900.
25. Garcea G, Berry DP, Jones DJ et al. Consumption of the putative chemopreventive agent curcumin by cancer patients: assessment of curcumin levels in the colorectum and their pharmacodynamic consequences. *Cancer Epidemiol Biomarkers Prev* 2005;14:120-125.
26. Sharma RA, McLelland HR, Hill KA et al. Pharmacodynamic and pharmacokinetic study of oral *Curcuma* extract in patients with colorectal cancer. *Clin Cancer Res* 2001;7:1894-1900.
27. Shoba G, Joy D, Joseph T et al. Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. *Planta Med* 1998;64:353-356.

28. Thapliyal R, Maru GB. Inhibition of cytochrome P450 isozymes by curcumins in vitro and in vivo. *Food Chem Toxicol* 2001;39:541-547.
29. Thapliyal R, Deshpande SS, Maru GB. Effects of turmeric on the activities of benzo(a)pyrene-induced cytochrome P-450 isozymes. *J Environ Pathol Toxicol Oncol* 2001;20:59-63.
30. Oetari S, Sudibyo M, Commandeur JN et al. Effects of curcumin on cytochrome P450 and glutathione S-transferase activities in rat liver. *Biochem Pharmacol* 1996;51:39-45.
31. Rinaldi AL, Morse MA, Fields HW et al. Curcumin activates the aryl hydrocarbon receptor yet significantly inhibits (-)-benzo(a)pyrene-7R-trans-7,8-dihydrodiol bioactivation in oral squamous cell carcinoma cells and oral mucosa. *Cancer Res* 2002;62:5451-5456.
32. Raucy JL. Regulation of CYP3A4 expression in human hepatocytes by pharmaceuticals and natural products. *Drug Metab Dispos* 2003;31:533-539.
33. Azuine MA, Bhide SV. Chemopreventive effect of turmeric against stomach and skin tumors induced by chemical carcinogens in Swiss mice. *Nutr Cancer* 1992;17:77-83.
34. Iqbal M, Sharma SD, Okazaki Y et al. Dietary supplementation of curcumin enhances antioxidant and phase II metabolizing enzymes in ddY male mice: possible role in protection against chemical carcinogenesis and toxicity. *Pharmacol Toxicol* 2003;92:33-38.
35. Zhou S, Lim LY, Chowbay B. Herbal Modulation of P-glycoprotein. *Drug Metab Rev* 2004;36:57-104.
36. Nabekura T, Kamiyama S, Kitagawa S. Effects of dietary chemopreventive phytochemicals on P-glycoprotein function. *Biochem Biophys Res Commun* 2005;327:866-870.
37. Anuchapreeda S, Leechanachai P, Smith MM et al. Modulation of P-glycoprotein expression and function by curcumin in multidrug-resistant human KB cells. *Biochem Pharmacol* 2002;64:573-582.
38. Chearwae W, Anuchapreeda S, Nandigama K et al. Biochemical mechanism of modulation of human P-glycoprotein (ABCB1) by curcumin I, II, and III purified from turmeric powder. *Biochem Pharmacol* 2004;68:2043-2052.
39. Venkatesan N, Punithavathi V, Chandrakasan G. Curcumin protects bleomycin-induced lung injury in rats. *Life Sci* 1997;61:PL51-58.
40. Punithavathi D, Venkatesan N, Babu M. Curcumin inhibition of bleomycin-induced pulmonary fibrosis in rats. *Br J Pharmacol* 2000;131:169-172.
41. Navis I, Sriganth P, Premalatha B. Dietary curcumin with cisplatin administration modulates tumour marker indices in experimental fibrosarcoma. *Pharmacol Res* 1999;39:175-179.
42. Notarbartolo M, Poma P, Perri D et al. Antitumor effects of curcumin, alone or in combination with cisplatin or doxorubicin, on human hepatic cancer cells: analysis of their possible relationship to changes in NF- κ B activation levels and in IAP gene expression. *Cancer Lett* 2005;224:53-65.
43. Venkatesan N, Chandrakasan G. Modulation of cyclophosphamide-induced early lung injury by curcumin, an anti-inflammatory antioxidant. *Mol Cell Biochem* 1995;142:79-87.
44. Chueh SC, Lai MK, Liu IS et al. Curcumin enhances the immunosuppressive activity of cyclosporine in rat cardiac allografts and in mixed lymphocyte reactions. *Transplant Proc* 2003;35:1603-1605.
45. Ranjan D, Johnston TD, Wu G et al. Curcumin blocks cyclosporine A-resistant CD28 costimulatory pathway of human T-cell proliferation. *J Surg Res* 1998;77:174-178.
46. Ranjan D, Chen C, Johnston TD et al. Curcumin inhibits mitogen-stimulated lymphocyte proliferation, NF κ B activation, and IL-2 signaling. *J Surg Res* 2004;121:171-177.
47. Natarajan C, Bright JJ. Curcumin inhibits experimental allergic encephalomyelitis by blocking IL-12 signaling through Janus kinase-STAT pathway in T lymphocytes. *J Immunol* 2002;168:6506-6513.
48. Deters M, Klabunde T, Meyer H et al. Effects of curcumin on cyclosporine-induced cholestasis and hypercholesterolemia and on cyclosporine metabolism in the rat. *Planta Med* 2003;69:337-343.
49. Jones EA, Shoskes DA. The effect of mycophenolate mofetil and polyphenolic bioflavonoids on renal ischemia reperfusion injury and repair. *J Urol* 2000;163:999-1004.
50. Venkatesan N. Curcumin attenuation of acute Adriamycin myocardial toxicity in rats. *Br J Pharmacol* 1998;124:425-427.
51. Venkatesan N, Punithavathi D, Arumugam V. Curcumin prevents Adriamycin nephrotoxicity in rats. *Br J Pharmacol* 2000;129:231-234.
52. Chuang SE, Yeh PY, Lu YS et al. Basal levels and patterns of anticancer drug-induced activation of nuclear factor-kappaB (NF- κ B), and its attenuation by tamoxifen, dexamethasone, and curcumin in carcinoma cells. *Biochem Pharmacol* 2002;63:1709-1716.
53. Harbottle A, Daly AK, Atherton K, Campbell FC. Role of glutathione S-transferase P1, P-glycoprotein and multidrug resistance-associated protein 1 in acquired doxorubicin resistance. *Int J Cancer* 2001;92:777-783.

Citations and Reference Literature: Turmeric/Curcumin

54. Rukkumani R, Aruna K, Varma PS et al. Comparative effects of curcumin and an analog of curcumin on alcohol and PUFA induced oxidative stress. *J Pharm Pharm Sci* 2004;7:274-283.
55. Nanji AA, Jokelainen K, Tipoe GL et al. Curcumin prevents alcohol-induced liver disease in rats by inhibiting the expression of NF-kappa B-dependent genes. *Am J Physiol Gastrointest Liver Physiol* 2003;284:G321-327.
56. Rajakrishnan V, Jayadeep A, Arun OS et al. Changes in the prostaglandin levels in alcohol toxicity: effect of curcumin and N-acetylcysteine. *J Nutr Biochem* 2000;11:509-514.
57. Gukovsky I, Reyes CN, Vaquero EC et al. Curcumin ameliorates ethanol and nonethanol experimental pancreatitis. *Am J Physiol Gastrointest Liver Physiol* 2003;284:G85-G95.
58. Rajakrishnan V, Viswanathan P, Rajasekharan KN, Menon VP. Neuroprotective role of curcumin from *Curcuma longa* on ethanol-induced brain damage. *Phytother Res* 1999;13:571-574.
59. Rukkumani R, Aruna K, Varma PS, Menon VP. Curcumin influences hepatic expression patterns of matrix metalloproteinases in liver toxicity. *Ital J Biochem* 2004;53:61-66.
60. Naik RS, Mujumdar AM, Ghaskadbi S. Protection of liver cells from ethanol cytotoxicity by curcumin in liver slice culture in vitro. *J Ethnopharmacol* 2004;95:31-37.
61. Rajakrishnan V, Shinee SJ, Sudhakaran PR, Menon VP. Effect of curcumin on ethanol-induced stress on mononuclear cells. *Phytother Res* 2002;16:171-173.
62. Rafatullah S, Tariq M, Al-Yahya MA et al. Evaluation of turmeric (*Curcuma longa*) for gastric and duodenal antiulcer activity in rats. *J Ethnopharmacol* 1990;29:25-34.
63. Swarnakar S, Ganguly K, Kundu P et al. Curcumin regulates expression and activity of matrix metalloproteinases 9 and 2 during prevention and healing of indomethacin-induced gastric ulcer. *J Biol Chem* 2005;280:9409-9415.
64. Kositchaiwat C, Kositchaiwat S, Havanondha J. *Curcuma longa* Linn. in the treatment of gastric ulcer comparison to liquid antacid: a controlled clinical trial. *J Med Assoc Thai* 1993;76:601-605.
65. Menon LG, Kuttan R, Kuttan G. Anti-metastatic activity of curcumin and catechin. *Cancer Lett* 1999;141:159-165.
66. Bava SV, Puliappadamba VT, Deepti A et al. Sensitization of Taxol-induced apoptosis by curcumin involves down-regulation of nuclear factor-kappaB and the serine/threonine kinase Akt and is independent of tubulin polymerization. *J Biol Chem* 2005;280:6301-6308.
67. Srivastava R, Puri V, Srimal RC, Dhawan BN. Effect of curcumin on platelet aggregation and vascular prostacyclin synthesis. *Arzneimittelforschung* 1986;36:715-717.
68. Srivastava R, Dikshit M, Srimal RC, Dhawan BN. Anti-thrombotic effect of curcumin. *Thromb Res* 1985;40:413-417.
69. Srivastava KC, Bordia A, Verma SK. Curcumin, a major component of food spice turmeric (*Curcuma longa*) inhibits aggregation and alters eicosanoid metabolism in human blood platelets. *Prostaglandins Leukot Essent Fatty Acids* 1995;52:223-227.
70. Shah BH, Nawaz Z, Pertani SA et al. Inhibitory effect of curcumin, a food spice from turmeric, on platelet-activating factor- and arachidonic acid-mediated platelet aggregation through inhibition of thromboxane formation and Ca²⁺ signaling. *Biochem Pharmacol* 1999;58:1167-1172.
71. Nishiyama T, Mae T, Kishida H et al. Curcuminoids and sesquiterpenoids in turmeric (*Curcuma longa* L.) suppress an increase in blood glucose level in type 2 diabetic KK-Ay mice. *J Agric Food Chem* 2005;53:959-963.
72. Kuroda M, Mimaki Y, Nishiyama T et al. Hypoglycemic effects of turmeric (*Curcuma longa* L. rhizomes) on genetically diabetic KK-Ay mice. *Biol Pharm Bull* 2005;28:937-939.
73. Suryanarayana P, Saraswat M, Mrudula T et al. Curcumin and turmeric delay streptozotocin-induced diabetic cataract in rats. *Invest Ophthalmol Vis Sci* 2005;46:2092-2099.
74. Arafa HM. Curcumin attenuates diet-induced hypercholesterolemia in rats. *Med Sci Monit* 2005;11:BR228-BR234.
75. Osawa T, Kato Y. Protective role of antioxidative food factors in oxidative stress caused by hyperglycemia. *Ann N Y Acad Sci* 2005;1043:440-451.